Allogene Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Allogene Therapeutics, Inc. (ALLO) on September 2, 2026, reporting an event that occurred on August 31, 2026. The filing pertains to a significant change in the company's executive leadership.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial statements or performance data.
Material Changes
The primary material change reported is the departure of a senior executive:
- Geoffrey Parker, Executive Vice President and Chief Financial Officer (CFO) and principal financial officer, has provided notice of his retirement.
- The retirement is effective November 6, 2026.
- Mr. Parker will retire from all capacities with the Company.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, outlook, management commentary on financial performance, or specific risk factors beyond the leadership transition. No unusual items or contingencies were disclosed in this specific report.
Key Facts for Investor Verification
- Verify the timeline for the appointment of a new Chief Financial Officer to replace Geoffrey Parker.
- Confirm whether Mr. Parker's departure is part of a broader executive restructuring.
- Review subsequent filings for any impact on the company's financial reporting or strategic direction following the CFO's departure.